GlobeNewswire: Industry News on Medical Supplies Contains the last 10 of 8080 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:57:35ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853960/0/en/Ocean-Biomedical-NASDAQ-OCEA-Congratulates-JV-Partner-Virion-Therapeutics-on-Promising-First-Ever-Human-Phase-1B-Clinical-Safety-Data-for-Their-Lead-Checkpoint-Modifier-Containing-.html?f=22&fvtc=3&fvtv=4537Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL2024-03-28T12:01:00Z<![CDATA[Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27 - 31.]]>https://www.globenewswire.com/news-release/2024/03/28/2853920/0/en/CG-Oncology-to-Present-Results-on-Cretostimogene-at-the-AUA-2024-Annual-Meeting.html?f=22&fvtc=3&fvtv=4537CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting2024-03-28T12:00:00Z<![CDATA[- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - - New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -]]>https://www.globenewswire.com/news-release/2024/03/26/2852700/0/en/2023-Shareholders-General-Meeting.html?f=22&fvtc=3&fvtv=45372023 Shareholders General Meeting2024-03-26T19:00:00Z<![CDATA[Press release Ecully, March 26, 2024 – 8.00 p.m.]]>https://www.globenewswire.com/news-release/2024/03/26/2852700/0/fr/Assembl%C3%A9e-G%C3%A9n%C3%A9rale-2023.html?f=22&fvtc=3&fvtv=4537Assemblée Générale 2023 2024-03-26T19:00:00Z<![CDATA[Communiqué de presse Ecully, le 26 mars 2024 – 20h]]>https://www.globenewswire.com/news-release/2024/03/21/2850242/0/en/United-Health-Products-Submits-Full-FDA-PMA-Application.html?f=22&fvtc=3&fvtv=4537United Health Products Submits Full FDA PMA Application2024-03-21T12:37:48Z<![CDATA[MOUNT LAUREL, NJ, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval application process.]]>https://www.globenewswire.com/news-release/2024/03/20/2849673/0/en/EssilorLuxottica-Disclosure-of-Share-Capital-and-Voting-Rights-Outstanding-as-of-March-13-2024.html?f=22&fvtc=3&fvtv=4537EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 13, 20242024-03-20T17:00:00Z<![CDATA[Disclosure of Share Capital and Voting Rights Outstanding as of March 13, 2024]]>https://www.globenewswire.com/news-release/2024/03/20/2849673/0/fr/EssilorLuxottica-Nombre-total-de-droits-de-vote-et-d-actions-composant-le-capital-social-au-13-mars-2024.html?f=22&fvtc=3&fvtv=4537EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 13 mars 2024 2024-03-20T17:00:00Z<![CDATA[Nombre total de droits de vote et d’actions composant le capital social au 13 mars 2024]]>https://www.globenewswire.com/news-release/2024/03/19/2848891/0/en/Impressive-3-3M-investment-in-Basic-Mental-Health-Research.html?f=22&fvtc=3&fvtv=4537Impressive $3.3M investment in Basic Mental Health Research2024-03-19T17:42:43Z<![CDATA[Three recipients, along with their dedicated research teams, receive $1.1 million each to advance our understanding of mental health conditions at a fundamental level Three recipients, along with their dedicated research teams, receive $1.1 million each to advance our understanding of mental health conditions at a fundamental level]]>From left to right: Dr. Stephanie Borgland, Dr, Liisa Galea, and Dr. Susan GeorgeThe recipients of the Basics of Better Mental Health Programhttps://www.globenewswire.com/news-release/2024/03/19/2848891/0/fr/Investissement-important-de-3-3-M-dans-la-recherche-fondamentale-en-sant%C3%A9-mentale.html?f=22&fvtc=3&fvtv=4537Investissement important de 3,3 M$ dans la recherche fondamentale en santé mentale2024-03-19T17:42:43Z<![CDATA[Trois lauréats et leurs équipes de recherche attitrées reçoivent chacun 1,1 million de dollars pour faire progresser notre compréhension des problèmes de santé mentale à un niveau fondamental. Trois lauréats et leurs équipes de recherche attitrées reçoivent chacun 1,1 million de dollars pour faire progresser notre compréhension des problèmes de santé mentale à un niveau fondamental.]]>De gauche à droite : Stephanie Borgland, Liisa Galea et Susan George.Les lauréats du programme Les bases d’une meilleure santé mentalehttps://www.globenewswire.com/news-release/2024/03/13/2845848/0/en/Anika-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results.html?f=22&fvtc=3&fvtv=4537Anika Reports Fourth Quarter and Year-End 2023 Financial Results2024-03-13T20:05:34Z<![CDATA[Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year]]>